Stratagene is hoping that a US District Court judge in Texas will decrease the $7.8 million in damages a jury awarded to Invitrogen in a patent-infringement case, President and CEO Joe Sorge said during a conference call this week.
The Invitrogen case is one of several legal disputes in which Stratagene is embroiled and hopes to wrap up this year, either through final court rulings or settlements, according to Sorge.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.